Want to see HK:3347 full AI Analyst Report?
Top Page
Hangzhou Tigermed Consulting Co., Ltd. Class H
(3347)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$42.00
â–¼(-22.22% Downside)
Action:Reiterated
Date:08/29/26
The score is driven primarily by financial stability (strong balance sheet and positive, improving free cash flow), which helps limit downside risk. This is tempered by weakened profitability versus prior years and a demanding valuation (high P/E). Technicals are neutral-to-mixed, offering only modest support.
Positive Factors
Low Leverage
Conservative leverage and a substantial equity base provide financial flexibility for a CRO operating through varied development cycles. This reduces balance-sheet strain and supports continued investment in clinical research capabilities without dependence on heavy borrowing.
Negative Factors
Profitability Compression
The sustained decline in gross and net margins indicates weaker operating leverage, pricing, or cost absorption than in prior years. Unless margins recover, revenue growth may translate into less profit and limit returns from the CRO platform.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Conservative leverage and a substantial equity base provide financial flexibility for a CRO operating through varied development cycles. This reduces balance-sheet strain and supports continued investment in clinical research capabilities without dependence on heavy borrowing.
Read all positive factors
Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$44.44B
Dividend Yield0.37%
Average Volume (3M)1.80M
Price to Earnings (P/E)625.0
Beta (1Y)1.77
Revenue Growth16.21%
EPS Growth-82.18%
CountryHK
Employees11,130
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.10
Shares Outstanding123,124,800
10 Day Avg. Volume1,941,431
30 Day Avg. Volume1,797,176
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$52.42Price Target Upside-2.93% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.67
Revenue Forecast (FY)HK$9.01B
Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical tr...
How the Company Makes Money
Hangzhou Tigermed Consulting Co., Ltd. primarily makes money by charging clients (pharmaceutical, biotech, and medical device companies) service fees under CRO contracts to plan, manage, and execute development programs. Key revenue streams typica...
Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
82
Very Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.28B | 6.83B | 6.60B | 7.38B | 7.09B | 5.21B |
| Gross Profit | 1.88B | 1.87B | 2.24B | 2.85B | 2.81B | 2.27B |
| EBITDA | 1.83B | 1.42B | 1.13B | 2.91B | 2.93B | 3.90B |
| Net Income | 225.70M | 887.89M | 405.14M | 2.02B | 2.01B | 2.87B |
Balance Sheet | ||||||
| Total Assets | 27.89B | 28.36B | 28.67B | 29.68B | 27.45B | 23.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.15B | 1.84B | 2.13B | 7.46B | 7.88B | 8.57B |
| Total Debt | 2.35B | 1.47B | 2.63B | 2.83B | 2.80B | 1.19B |
| Total Liabilities | 4.79B | 4.10B | 4.61B | 5.23B | 4.77B | 3.14B |
| Stockholders Equity | 19.47B | 20.96B | 20.67B | 21.03B | 19.58B | 18.12B |
Cash Flow | ||||||
| Free Cash Flow | 1.20B | 903.72M | 740.45M | 836.68M | 908.90M | 1.06B |
| Operating Cash Flow | 1.42B | 1.12B | 1.10B | 1.15B | 1.36B | 1.42B |
| Investing Cash Flow | 218.18M | 491.56M | -4.74B | -1.53B | -2.79B | -2.78B |
| Financing Cash Flow | -1.24B | -1.93B | -1.70B | -7.81M | 809.25M | -163.09M |
Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis
Negative
54.00
Price Trends
38.43
Positive
37.00
Positive
40.70
Negative
Market Momentum
0.28
Positive
47.89
Neutral
25.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Negative. The current price of 54 is above the 20-day moving average (MA) of 40.15, above the 50-day MA of 38.43, and above the 200-day MA of 40.70, indicating a neutral trend. The MACD of 0.28 indicates Positive momentum. The RSI at 47.89 is Neutral, neither overbought nor oversold. The STOCH value of 25.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3347.
Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$535.38B | 20.35 | 27.24% | 1.25% | 29.92% | 65.54% | |
69 Neutral | HK$92.33B | 51.09 | 14.00% | ― | 41.52% | 17.10% | |
64 Neutral | HK$34.30B | 32.36 | 11.59% | 0.61% | -5.01% | 243.16% | |
63 Neutral | HK$44.44B | 625.00 | 0.44% | 0.37% | 16.21% | -82.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
38.80
-12.61
-24.53%
HK:2359
WuXi AppTec Co., Ltd. Class H
191.70
79.41
70.72%
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
22.54
1.96
9.55%
HK:6667
Mega Genomics Limited
7.07
0.04
0.54%
HK:9860
ADICON Holdings Limited
4.06
-3.09
-43.22%
HK:2268
WuXi XDC Cayman, Inc.
72.55
7.95
12.31%
Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events
Tigermed Unveils 2026 Restricted A Share Incentive Scheme to Align Talent and Growth
Aug 28, 2026
Tigermed’s board has approved the proposed adoption of a 2026 Restricted A Share Incentive Scheme, accompanying assessment management measures, and authorization for the board to handle related implementation matters, all subject to sharehol...
Tigermed Cancels Remaining Treasury Shares to Cut Registered Capital
Aug 28, 2026
Hangzhou Tigermed Consulting Co., Ltd. has decided to cancel all remaining 5,883,780 A-share treasury shares previously repurchased under its 2024 buyback plan, shifting their intended use from future equity incentive or employee stock ownership s...
Tigermed Board Approves New 2026 Plan for Remaining H Share Proceeds
Aug 28, 2026
Hangzhou Tigermed Consulting Co., Ltd., a Chinese clinical research services provider listed via H shares in Hong Kong, has raised net proceeds of approximately HK$11.8 billion from its H share offering. The company has repeatedly adjusted the dep...
Tigermed Grows Revenue but Swings to Interim Loss on One-Off Items
Aug 28, 2026
Hangzhou Tigermed Consulting reported a 14.1% year-on-year rise in first-half 2026 revenue to RMB3.71 billion, with gross profit up 4.3% to RMB1.02 billion, reflecting continued business expansion in its contract research services. However, the co...
Tigermed Sets August Board Meeting to Approve Interim Results and Weigh Dividend
Aug 18, 2026
Hangzhou Tigermed Consulting Co., Ltd. has scheduled a board meeting for August 28, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their public release. The board will also consid...
Tigermed Reschedules Final Dividend Payment Date for H Shares
Jun 30, 2026
Hangzhou Tigermed Consulting Co., Ltd., a Chinese contract research organization with H shares listed in Hong Kong and A shares in Shenzhen, focuses on providing clinical research and consulting services to pharmaceutical and biotech clients. Its ...
Tigermed Updates 2025 Final Dividend Payment Date and Sets Cross-Border Tax Terms
Jun 30, 2026
Hangzhou Tigermed Consulting Co., Ltd., a clinical research and biopharmaceutical services company listed in Hong Kong and Shenzhen, caters to both domestic and international investors via A shares and H shares. Its shareholder base includes mainl...
Tigermed shareholders approve all resolutions at June extraordinary meetings
Jun 9, 2026
Hangzhou Tigermed Consulting Co., Ltd. held its 2026 second extraordinary general meeting and separate A share and H share class meetings in Hangzhou on June 9, where all resolutions put to shareholders were approved by poll. The meetings were cha...
Tigermed Secures Shareholder Approval at 2025 AGM and 2026 Class Meetings
Jun 2, 2026
Hangzhou Tigermed Consulting Co., Ltd., a leading Chinese contract research organization serving pharmaceutical and biotech clients, operates through both A shares on the Shenzhen Stock Exchange and H shares in Hong Kong. Its business centers on c...
Tigermed Clarifies Board Roles to Strengthen Governance Structure
Jun 2, 2026
Hangzhou Tigermed Consulting has updated its board composition, detailing the allocation of directors across key governance committees, including strategy development, remuneration and evaluation, audit, and nomination. The announcement highlights...
Hangzhou Tigermed Overhauls Board Roles and Senior Management for Sixth Term
Jun 2, 2026
Hangzhou Tigermed Consulting Co., Ltd. announced the composition of its sixth board of directors and confirmed that executive director Dr. Ye Xiaoping has been elected chairman for the new board term starting June 2, 2026. Independent non-executiv...
Tigermed Elects Wu Hao as Employee Director for Sixth Board Term
Jun 2, 2026
Hangzhou Tigermed Consulting has announced the election of Wu Hao as the employee director for its sixth board term, following a vote at the company’s employee representative meeting. His appointment will take effect once the new board is ap...
Tigermed Updates Final 2025 Dividend Terms for Cross-Border Shareholders
Jun 2, 2026
Hangzhou Tigermed Consulting Co., Ltd., a China-based clinical research and pharmaceutical services group listed in Hong Kong, provides contract research and related consulting services to biopharmaceutical and healthcare companies. Its Hong Kong ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.